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Bile acids are amphipathic steroids made from choles-
terol in the liver that act as facilitators of intestinal fat 
absorption (1). It has become clear that this versatile group 
of molecules also regulates an array of physiological pro-
cesses that are vital to hepatic, intestinal, and metabolic 
health via activation of the nuclear receptor, FXR (NR1H4), 
and the membrane-bound receptor, TGR5 (GPBAR1) (1, 2). 
Bile acids have also been shown to be able to activate the 
nuclear receptors, vitamin D receptor and pregnane X re-
ceptor, as well as sphingosine 1-phosphate receptor 2 (3–5). 
The combined properties of being small molecules with 
potent physiological effects have driven efforts to utilize 
bile acids and/or their signaling systems for therapeutic 
applications (2). Obeticholic acid, a potent FXR agonist, 
has been approved for the treatment of primary biliary 
cholangitis (6). Obeticholic acid was also shown to increase 
insulin sensitivity in type 2 diabetes patients as well as to 
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improve markers of liver inflammation and fibrosis (7). 
Effectiveness of obeticholic acid treatment was also con-
firmed in a multicenter trial with noncirrhotic nonalcoholic 
steatohepatitis patients (8). Interestingly, despite hepatic 
improvements, this study also showed elevated insulin 
levels and increased values for the homeostatic model as-
sessment of insulin resistance index. Yet, the many implica-
tions of bile acid signaling pathways on energy metabolism 
have inspired the development of FXR agonists aiming at 
obesity-related diseases that are currently advancing into 
clinical trials (9–12).
FXR activation by bile acids (13–15) provides these natu-
ral detergents with a means to modulate their own synthesis 
in the liver and their transport within the enterohepatic cir-
culation (1, 16–18). Accordingly, FXR shows highest expres-
sion in the liver and intestine (19). Yet, FXR expression is 
not confined to these sites, but also occurs in several other 
organs and tissues, including kidney, adrenal glands, and 
vascular wall as well as adipose tissue. The physiological func-
tions of FXR at these locations have largely remained elu-
sive. In view of the recent developments toward the use of 
FXR agonists as therapeutic agents, it is of crucial impor-
tance to have full understanding of the (patho)physiological 
role of FXR in specific non-enterohepatic locations, includ-
ing adipose tissue. This is of particular importance because 
obesity-associated diseases, such as type 2 diabetes and dyslip-
idemia, are characterized by adipose tissue dysfunction (20).
The capacity for dynamic remodeling of white adipose 
tissue (WAT) and its role in control of whole-body metabo-
lism through cross-talk with other tissues and organs by 
metabolites (predominantly free fatty acids) and hormones 
(i.e., adipokines and lipokines) delineate the complexity of 
metabolic control (21). Whereas subcutaneous WAT is the 
sole site in the body that can accumulate lipids without det-
rimental consequences, expansion of visceral adipose de-
pots and, particularly, ectopic lipid deposition in liver and 
muscle have major adverse health effects (22). Expansion 
by formation of new adipocytes (hyperplasia) is a hallmark 
of healthy WAT, whereas growth by enlargement of adipo-
cyte size (i.e., hypertrophy) is associated with adverse meta-
bolic outcomes (23).
A role for FXR in adipose tissue, where it is expressed at 
relatively low levels, was first proposed when FXR/ mice 
were shown to exhibit small adipocytes, and FXR was subse-
quently shown to promote adipocyte differentiation in 
vitro (24–26). These initial studies further revealed insulin 
resistance in adipose tissue of mice lacking Fxr. Unexpect-
edly, whole-body FXR-deficient mice were also shown to be 
resistant to the development of obesity when fed a high-fat 
diet (HFD) or after crossbreeding with a genetic model of 
obesity, i.e., ob/ob mice. Both models showed improved glu-
cose homeostasis as well as increased adipose insulin sensitiv-
ity (27). Interestingly, Fxr expression in adipose tissues 
appeared to be decreased in mouse models of obesity (24). 
Yet, the direct contribution of adipocytic FXR in the devel-
opment of these striking metabolic phenotypes has remained 
elusive.
Here, we describe the metabolic consequences of mod-
erate (3- to 5-fold) overexpression of human FXR under 
the control of the aP2 (Fabp4) promoter in mice to directly 
address FXR function in adipose tissue. These studies show 
that, in line with the small adipocytes observed in FXR/ 
mice (24), transgenic mice expressing human FXR in 
adipose tissue (aP2-hFXR mice) display a marked adipo-
cyte hypertrophy. We examined the impact of FXR overex-
pression on WAT functioning under basal conditions as 
well as in response to metabolic stressors, such as diet- and 
age-induced obesity. These studies establish that FXR is a 
key determinant of adipocyte size and fat tissue architec-
ture, as sustained FXR expression in adipose tissue limits its 
storage capacity, promotes adipose tissue fibrosis, and ulti-
mately drives ectopic lipid accumulation and development 
of whole-body insulin resistance.
MATERIAL AND METHODS
Transgene construction and generation of transgenic  
aP2-hFXR mice
The individual expression plasmids containing the mouse aP2 
promoter in pBleuscript II SK(+) and the full-length open read-
ing frame of the human FXR2 in pCDNA3.1/TOPO were gener-
ous gifts from Dr. R. E. Hammer (28) and Dr. R. Mukherjee (29), 
respectively.
The 5.4 kbp fragment of aP2 promoter was excised from the 
pBleuscript II SK(+) using KpnI-SmaI restriction enzymes and 
ligated into the KpnI and SmaI sites of the pGEM-7Zf(+) vector 
(Promega, Madison, WI). By PCR amplification, SmaI-SmaI 
restriction sites were cloned onto the human FXR2 fragment 
(using forward primer cccgggATGGGATCAAAAATGAATCT and 
reverse primer cccgggAGAATAGAATGACACCTACT). The re-
sulting 1.9 kbp SmaI-SmaI human FXR2 fragment was cloned 
into the pCRTMII vector (Invitrogen, Breda, The Netherlands). 
After amplification, this fragment was excised, gel purified, and 
ligated to SmaI-SmaI sites of the pGEM-7Zf(+) containing the 5.4 
kbp aP2 promoter fragment. The orientation of the human FXR 
gene was verified using gel-based restriction control and the plas-
mid was sequence verified for the presence of the correct frag-
ment. Adipocyte-specific human-FXR transgenic mice (aP2-hFXR 
mice) were generated by microinjection of the construct in fertil-
ized FVB/NHsd eggs. The clone with the highest human-FXR 
mRNA level was recovered. Wild-type littermates were used as a 
control. aP2-hFXR mice were mated with whole-body Fxr-deficient 
(FXR/) mice in two steps, generating progeny including 
FXR/ and aP2-hFXR mice on a FXR/ background. Male mice 
used in this study were housed in a light (12:12 h)- and tempera-
ture (21°C)-controlled facility and received laboratory chow 
(RMH-B) and water ad libitum. When indicated, mice were fed a 
HFD containing 60% calories from fat, composed of 36% (w/w) 
beef fat (diets were obtained from Abdiets, Woerden, The 
Netherlands). Fat and lean mass was determined by MRI (Minispec, 
LF 90 II; Brüker, Billerica, MA). Four hour-fasted animals were 
euthanized under anesthesia, and organs and tissues were care-
fully dissected and weighed. All experimental procedures were 
approved by the review board of the Animal Care and Use Com-
mittee of the Groningen University in accordance with local 
regulations for use of experimental animals.
Histology and adipocyte size determination
The samples from liver and WAT fat depots were fixed in 4% 
neutral buffered paraformaldehyde, embedded in paraffin, cut 
into 4 m sections, and stained with either H&E or picrosirius red 
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staining by standard procedures. Cell area of three times sixty 
adipocytes per animal (n = 6–8 per group) was quantified using 
image analysis software (Qwin; Leica, Wetzlar, Germany). Crown-
like structure abundance was determined in H&E-stained sections 
by counting CLS prevalence per square millimeter in whole sec-
tions of at least 10 mm2.
Indirect calorimetry
Mice were placed in an open-circuit indirect calorimeter sys-
tem 24 h prior to the start of the experiment with free access to 
water and food (TSE Systems GmbH, Bad Homburg, Germany). 
Flow rates were measured and controlled with a mass flow control-
ler. O2 and CO2 concentrations of dried inlet and outlet air from 
each chamber were measured every 10 min. Infrared light-beam 
frames surrounding the home cage measured activity in the x and y 
direction. Data were analyzed using LabMaster software (TSE 
Systems GmbH). Energy expenditure was calculated using the 
following equation: EE (kcal/h) = [3.941 × VO2 (ml/h) + 1.106 × 
VCO2 (ml/h)]/1,000.
Fat absorption
Fat absorption was determined as described previously (30).
Hepatic de novo lipogenesis
Labeling of the acetyl-CoA pool was assessed by providing 
[1-13C]acetate (Isotec/Sigma-Aldrich, St. Louis, MO) in drinking 
water as previously described by Jung et al. (31). Lipids in liver 
homogenates were fractionated using Isolute NH2 columns 
(Biotage AB, Uppsala, Sweden) and subsequently converted to 
their pentafluorobenzyl derivatives.
GC-MS measurements of fatty acids and calculations of de novo 
lipogenesis and chain elongation of fatty acids were performed 
essentially as described (32). Pre-existing fatty acids (percent) were 
calculated by the following equation: 100%de novo synthesis 
(%)chain elongation (%) originating fatty acids.
Real-time quantitative reverse transcription-PCR
Total RNA was isolated from tissues using TRIreagent (Sigma-
Aldrich). cDNA was synthesized by reverse transcription using 
reverse transcriptase and random primers according to the manu-
facturer’s protocol. mRNA expression levels were analyzed by 
means of real-time PCR on a 7900HT FAST real-time PCR system 
using FAST PCR master mix and MicroAmp FAST optical 96-well 
reaction plates (Applied Biosystems Europe, Nieuwerkerk a/d 
IJssel, The Netherlands) using SYBR green and CT for all genes 
except Fxr that could only be detected using TaqMan. PCR results 
were normalized to 36b4 (Rplp0) mRNA levels. Primers and 
probe sequences are listed in Table 1.
Liver and plasma parameters
Hepatic lipids were extracted from homogenized livers in ice-
cold PBS; lipids were extracted according to Bligh and Dyer (33). 
Lipid profiles in liver and plasma were determined using com-
mercially available kits for free fatty acids, triglycerides, and cho-
lesterol (Wako, Neuss, Germany; Roche, Mannheim, Germany). 
Blood glucose and insulin concentrations were measured using a 
EuroFlash meter (Lifescan Benelux, Beerse, Belgium) and an 
ELISA (Mercodia, Uppsala, Sweden), respectively. For analysis of 
glucose kinetics, a trace amount of labeled 13-C glucose was 
injected intraperitoneally into 9 h-fasted mice and total glucose 
was measured every 10 min and blood spots were collected. 
Glucose kinetics were determined according to (34). Adipokine 
array was performed according to the manufacturer’s instruc-
tions (R&D Systems, Minneapolis, MN), using 50 l of pooled 
plasma from six animals per group.
Plasma bile acids
Bile acid concentration in plasma was measured in 25 l of 
homogenized plasma. An internal standard containing D4-cholate, 
D4-chenodeoxycholate, D4-glycocholate, D4-taurocholate, D4-
glycochenodeoxycholate, and D4-taurochenodeoxycholate was 
added. Samples were mixed and centrifuged at 15,900 g. The 
supernatant was evaporated under vacuum at 40°C and recon-
stituted in 100 l of 50% methanol. The bile acid profile was 
measured using LC-MS/MS as described (35).
Affymetrix microarray analysis
For the microarray analysis, total RNA was prepared from epi-
didymal WAT (eWAT) of 10-week-old wild-type and aP2-hFXR-
TG mice (n = 4 per group) using TRIreagent (Sigma-Aldrich). 
RNA was further purified using RNeasy MinElute micro columns 
(Qiagen, Venlo, The Netherlands). RNA integrity was checked 
on an Agilent 2100 bioanalyzer (Agilent Technologies, Amster-
dam, The Netherlands) using 6000 Nano Chips according to the 
manufacturer’s instructions. Five hundred nanograms of RNA 
were used for one cycle cRNA synthesis (Affymetrix, Santa Clara, 
CA). Hybridization, washing, and scanning of Affymetrix Gene 
Chip Mouse Gene 1.0 ST arrays were done according to standard 
Affymetrix protocols. Quality control, normalization (VSN), pre-
filtering (fold change 1.1), and statistics (IBMT) were performed 
in MADMAX (36). A list of significantly changed annotated 
genes, including FDR-corrected P-values (5%) was generated. All 
microarray data reported are described in accordance with MIAME 
guidelines and are available in the GEO database (GSE37248). 
Identification of overrepresented functional categories among 
responsive genes and their grouping into functionally related 
clusters was performed using DAVID 6.7 functional annotation 
clustering tool (37) and Gene Set Enrichment Analysis (GSEA) 
(38). Transcription factor analysis was performed with Metacore, 
Clarivate Analytics.
Adipose tissue culture and CILAIR
At 14 weeks of age, wild-type (n = 6) and aP2-hFXR (n = 5) mice 
were euthanized. eWAT was flushed with saline solution to remove 
blood from the tissue and carefully dissected. The adipose tissue 
culture protocol is described (39). The CILAIR protocol was 
described previously (40). Briefly, after mincing (20–80 mg pieces), 
washing, filtering, and centrifuging the adipose tissue, the tissue 
was weighed and tissue pieces of individual wild-type and 
aP2-hFXR mice were pooled and divided over three wild-type dishes 
(1.2 g per dish in 12 ml of medium) and three aP2-hFXR-TG 
dishes (0.75 g per dish in 7.5 ml of medium). Dishes with adipose 
tissue were incubated at 37°C at 5% CO2 with lysine and argi-
nine-free DMEM medium (D944; Sigma-Aldrich) supplemented 
with 50 g/ml gentamicin (15750; Invitrogen), 100 mg/l leucine-
HCl (L8912; Sigma-Aldrich), and 200 mg/l proline (P5607; 
Sigma-Aldrich) to deplete the 12C lysine and arginine pool in 
the tissue. The medium was renewed after 1, 16, 20, and 23.5 h. 
After the last wash, all six dishes received fresh DMEM medium 
containing 100 mg/l L-[13C6, 
14N2]lysine and 100 mg/l [
13C6, 
15N4]arginine (Cambridge Isotope Laboratories, Andover, CT). 
Tissues were maintained in culture for an additional 24 h to allow 
incorporation of the label into newly synthesized proteins. There-
after, media were collected and stored at 80°C until analysis. 
After concentration of the culture media to a final volume of ap-
proximately 30 l by ultrafiltration, medium samples were frac-
tionated by SDS-PAGE on 4–12% bis-Tris gel with a MOPS buffer 
(NuPAGE®-Novex; Invitrogen). Bands were visualized and whole 
lanes were excised into 25 pieces that were processed for tryptic 
digestion. Each gel piece was washed, in-gel reduced, washed, and 
rehydrated for 20 min by adding 5 ng/l of modified trypsin 
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(Promega) in 20 mM ammonium bicarbonate. Digestion was car-
ried out overnight at 37°C. After digestion, the peptides were 
extracted from the gel by drying the gel pieces by speed-vac, 
rehydrating with 0.1% trifluoroacetic acid, and dehydrating with 
0.1% trifluoroacetic acid in 100% ACN. The extracted peptides 
were dried by speed-vac and redissolved in a MS-compatible sol-
vent (0.1% formic acid). Separation of the resulting tryptic pep-
tide mixtures was performed by nanoscale reversed-phase LC-MS/
MS. Protein identification and data analyses were performed as 
described (32).
Minor adjustments made to this protocol were: 1) Selected 
mass range of m/z 300–1,100 in Analyst QS 1.1 software (Applied 
Biosystems, Carlsbad, CA). 2) Selected three abundant charged 
peptides were dynamically excluded for 90 s with 50 mmu mass 
tolerance. 3) ProteinPilot 3.0 software (Applied Biosystems) using 
the UniprotKB/Swiss-Prot database was used to generate peak 
lists. Chosen options within the program were: label, Lys+6, and 
Arg+10; Cys alkylation with iodoacetamide; trypsin digestion; gel-
based identification; species, Mus musculus; identification focus 
for biological modifications; thorough search.
Western blot
Tissue lysates were prepared in RIPA lysis buffer [Tris-HCL 
(pH 8), NaCl 138 mM, NP40 1%, KCL 2.7 mM, MgCl2 1 mM, 
glycerol 5%, EDTA 5 mM, Na3VO4 1 mM, NaF 20 mM, DTT 1 
mM, and protease inhibitor] and protein concentrations were 
quantified using the RC DC assay (Bio-Rad, Hercules, CA). Pro-
tein samples were subjected to SDS-PAGE (15% gels) and trans-
ferred to nitrocellulose using a Trans-Blot® Turbo™ transfer 
system (Bio-Rad). Membranes were blocked for 1 h at room tem-
perature in PBS containing 0.1% Tween and 2% milk powder and 
incubated for 16 h with primary antibodies at 4°C. Antibodies 
used in this study were: anti-lamin A/C (Cell Signaling), anti-
Col-1 (Southern Biotech, Birmingham, AL), and anti-GAPDH 
(Calbiochem, San Diego, CA). Proteins were detected by incubat-
ing the blot with HRP-conjugated donkey anti-rabbit (Life Sci-
ence; NA934) or HRP-conjugated rabbit anti-mouse (Dako; 
p0260) IgG for 1 h at room temperature. Bands were visualized 
using Supersignal West Dura substrate (Thermo Scientific, 
Waltham, MA) and ChemiDoc (Bio-Rad). Image Lab software 
(Bio-Rad) was used for densitometry.
Statistical analysis
Data are presented as mean ± SEM. Differences between 
groups were tested by nonparametric Mann-Whitney U-test using 
GraphPad Prism 5.00 software package (GraphPad Software, San 
Diego, CA). All values are given as mean ± SEM. Significance was 
indicated as *P < 0.05, **P < 0.01, and ***P < 0.001.
RESULTS
aP2-hFXR mice have reduced body weight and enlarged 
adipocytes
To explore the role of FXR in adipose tissue, we gener-
ated transgenic mice that overexpress FXR (NR1H4) 
under control of the aP2 (Fabp4) promoter. Specifically, a 
transgenic construct containing the mouse aP2 promoter 
region and the human FXR coding sequence was microin-
jected into fertilized mouse eggs (supplemental Fig. S1A). 
Transgenic founders were produced and characterization 
of two independent transgenic lines, expressing the high-
est levels of total FXR mRNA in fat tissues, revealed highly 
similar phenotypes. In the transgenic line used for these 
experiments (designated aP2-hFXR), the total FXR mRNA 
expression level was increased 5.8-, 3.1-, and 3.2-fold in 
eWAT, retroperitoneal WAT (rWAT), and subcutaneous 
inguinal WAT (iWAT), respectively, but expression was still 
modest when compared with expression of endogenous 
Fxr in liver and ileum (Fig. 1A).
Body weights of 14-week-old male transgenic mice were 
20–30% lower than those of control mice (Fig. 1B). Food 
intake was slightly reduced in aP2-hFXR mice (Fig. 1C). 
The decrease in body weight is unlikely due to reduced in-
testinal absorption efficiency, as dietary fat absorption was 
unaffected (supplemental Fig. S1B). A small but significant 
difference between aP2-hFXR mice and controls was ob-
served in locomotor activity during the light phase (Fig. 1D). 
As the effects of the absence of Fxr in whole-body FXR/ 
mice on carbohydrate metabolism were most apparent 
during fasting and refeeding (41, 42), indirect calorimetry 
was performed during fed, fasted, and refed conditions. 
Energy expenditure did not significantly differ between 
both groups under these conditions, and also not during 
fasting and refed conditions (Fig. 1E, supplemental Fig. S1C). 
Growth curves showed that the body weight difference was 
TABLE 1. Primers used in the study
Gene Forward Reverse
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Fig. 1. Adipose hFXR-overexpressing mice are small and have hypertrophic adipocytes. A: Quantitative real-time PCR of total FXR 
expression in WAT depots (epididymal, retroperitoneal, and inguinal), liver, ileum, kidney, adrenals, muscle, and heart of wild-type (wt) 
and adipocyte-specific FXR overexpressing mice (aP2-hFXR). Body weight (B), cumulative food intake from 6 to 13 weeks of age (C), 
and locomotor activity (D) of wild-type and aP2-hFXR mice. E: Energy expenditure at 21°C measured over 12 h light/12 h dark phase. 
F: Lean and fat mass after 13 weeks. WAT depot weights (G) and representative image of eWAT morphology showing adipocyte hyper-
trophy (H). I: Depot size of rWAT and eWAT 3 weeks after birth of wild-type and aP2-hFXR mice. J: Plasma bile acid composition and 
total amounts in wild-type and aP2-hFXR mice. Scale bar represents 100 m. All panels: n = 6–8 per group; data are represented as mean ± SEM; 
*P < 0.05, **P < 0.01, ***P < 0.001.
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already apparent from weaning onwards (supplemental 
Fig. S1D). Surprisingly, the reduced weight of aP2-hFXR 
mice compared with controls was not only due to a reduc-
tion in fat mass; reduced lean body mass accounted for most 
of the difference (Fig. 1F). WAT depot weights of chow-fed 
aP2-hFXR mice were comparable to those in wild-type con-
trols (Fig. 1G), particularly when normalized to body 
weight (data not shown). Histological examination of adi-
pose tissues, however, revealed that adipocytes from chow-
fed aP2-hFXR animals were markedly hypertrophic (Fig. 1H 
for eWAT, supplemental Fig. S1E for rWAT and iWAT).
To determine whether adipose tissue appearance is 
already affected early in development, WAT depots of very 
young aP2-hFXR mice were examined. Adipose depot de-
velopment initiates just prior to birth and continues in 
the weeks thereafter, depending on the depot; and there-
fore, WAT of very young mice provides the opportunity 
to focus on adipose tissue that predominantly develops 
by adipogenesis (43). rWAT and eWAT weights of aP2-hFXR 
mice were decreased compared with wild-type controls 
already at 3 weeks of age (Fig. 1I), despite a comparable 
histological appearance (supplemental Fig. S1F). Taken 
together, these results indicate a role for FXR in early life 
WAT development and functioning.
As aP2-driven expression has been reported to also affect 
macrophages, depending on the size of the promotor in 
the construct and the integration site (44), we isolated 
intraperitoneal macrophages from aP2-hFXR and wild-type 
mice. Despite the fact that hFXR expression could indeed 
be detected, expression of inflammatory and FXR marker 
genes was not affected in these cells (supplemental Fig. S1G). 
Expression levels of monocyte chemoattractant protein 1 
(Mcp1) and cluster of differentiation 68 (Cd68), a macro-
phage marker, were similar in eWAT of aP2-hFXR mice 
and controls (supplemental Fig. S1H), indicating no major 
effects of aP2-hFXR expression on macrophage attraction. 
To determine whether hFXR expression alters endocrine 
functions of adipose tissues, adipokine levels were analyzed 
in pooled plasma samples. We observed a 10–50% reduc-
tion in abundance for the majority of proteins that could 
be detected, including several adipokines that have been 
associated with inflammation and insulin resistance, such 
as dipeptidyl peptidase 4, soluble ICAM-1, macrophage 
colony-stimulating factor, pentraxin-2, and resistin (sup-
plemental Fig. S1I). Also, the classical adipokines, leptin 
and adiponectin, showed decreased levels, whereas fibro-
blast growth factor 21 that positively affects several aspects 
of metabolic syndrome was one of the few proteins with 
increased abundance (+34%).
As bile acids are the natural ligands for FXR, we analyzed 
plasma bile acid levels and, unexpectedly, found elevated 
plasma bile acids in aP2-hFXR mice with altered composi-
tion. Particularly, substantially higher levels of cholate and 
taurocholate in the transgenic mice compared with con-
trols were found (Fig. 1J). Hepatic expression levels of the 
major bile acid synthesis genes were analyzed, showing that 
Cyp7a1 and Cyp8b1 expression levels in aP2-hFXR mice 
were similar to those in control animals and, in line with this 
observation, no change in expression of small heterodimer 
partner (Shp) (Nr0b2) was observed (supplemental Fig. S1J). 
Minor but significant decreases were observed for Cyp27a1 
(18%) and Cyp2c70 (23%) mRNA levels. A more pro-
nounced 2-fold decrease was observed in the expression 
levels of the hepatic bile acid uptake transporters Ntcp and 
Oatp1a1 (supplemental Fig. S1J). Plasma aspartate trans-
aminase (AST) levels were unaffected in aP2-hFXR mice, 
while alanine transaminase (ALT) showed a slight increase 
but remained very close to baseline (5 U/ml for controls 
and 14 U/ml for aP2-hFXR, data not shown).
Adipose FXR stimulates extracellular matrix remodeling
To further establish the physiological role of FXR in 
WAT, adipocyte size distribution was analyzed in the differ-
ent depots. A clear shift in adipocyte size distribution as 
well as average adipocyte size was observed in chow-fed aP2-
hFXR mice compared with controls (Fig. 2A, eWAT; sup-
plemental Fig. S2A, rWAT and iWAT). As the reduced 
adipocyte size in FXR/ mice was one of the drivers of our 
initial interest toward investigating adipose FXR (24), aP2-
hFXR mice were crossbred to whole-body FXR knockout 
mice. These mice showed similar aspects in their phenotype 
as hFXR adipose overexpressors on the wild-type back-
ground did, including 20–30% lower body weights, stem-
ming from reduced lean mass (supplemental Fig. S2B) and 
comparable locomotor activity and energy expenditure as 
FXR/ controls (supplemental Fig. S2C, D). Adipose depot 
weights of FXR/ aP2-hFXR mice were similar to those of 
controls (Fig. 2B); yet, adipocyte hypertrophy was again ap-
parent (Fig. 2C, supplemental Fig. S2E). This hypertrophy 
was, however, somewhat less pronounced when compared 
with the hFXR-induced phenotype in the wild-type back-
ground (Fig. 2D, supplemental Fig. S2E, F).
To gain insight in the mode(s) of action by which the 
transcription factor FXR acts in WAT, Affymetrix micro-
array analysis was performed on eWAT samples obtained 
from chow-fed aP2-hFXR and wild-type mice. A total of 
1,372 genes were found to be differentially expressed. 
Annotation analysis using DAVID and GSEA showed that 
among the most significantly affected cellular components 
and enriched gene sets, the extracellular matrix (ECM) 
seemed to be clearly affected by the presence of aP2-hFXR 
(Fig. 3A). Several collagen-encoding genes were upregu-
lated, including the collagen VI (but not the endotrophin-
encoding 3 type), collagen I, IV, and XV genes, as well 
as other ECM factors like elastin, biglycan, and lumican, 
and ECM-modifying genes, such as cathepsins and metal-
loproteinases (supplemental Table S1).
Altered expression or activity of the master regulators of 
adipogenesis, PPAR and CAAT/enhancer-binding pro-
tein (C/EBP), could in theory account for the inability of 
adipose depot expansion in aP2-hFXR mice. A 26% and 
33% reduction in expression of these genes was observed. 
However, no striking differential expression of PPAR tar-
get genes between the groups was observed (supplemental 
Table S2). Wnt/-catenin signaling has been shown to be 
increased in FXR/ mice. In line with the reported down-
regulation of secreted inhibitors of Wnt signaling, Sfrp1 
and Sfrp5, in FXR/ mice (26), we observed upregulation 
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(2.01-fold and 2.65-fold, respectively) of these genes in 
eWAT of aP2-hFXR mice. However, downregulation of Wnt 
signaling target genes, as observed in vitro in pre-adipocytes 
(26), was not evident (supplemental Table S2). In line with 
the unaltered expression levels of Mcp1 and Cd68 (see sup-
plemental Fig. S1H), eWAT trancriptomics showed no dif-
ferential expression of established inflammation markers.
To assess the role of FXR in ECM remodeling in more 
detail, quantitative profiling of the eWAT secretome was 
performed ex vivo. This approach resulted in identifica-
tion of several proteins that were either more abundant or 
exclusively present in WAT from aP2-hFXR mice. Only a 
limited number of proteins showed a decreased abundance 
(Fig. 3B, supplemental Tables S3, S4) (40).
Overrepresentation of specific collagen families, such 
as fibril-forming collagens (COL1A1, COL5A2), fibril- 
associated collagens (FACIT; COL14A1, COL15A1), and 
beaded filament-forming collagens (COL6A1, COL6A5), 
and ECM components like laminin, fibronectin, biglycans, 
dermatopontin, and cadherin-5 were observed in aP2-hFXR 
WAT secretomes, in line with the outcome of the tran-
scriptome analysis.
To determine whether the observed increase in ECM 
protein synthesis actually leads to fibrosis in vivo and is not 
compensated by ECM degradation, specific fibrosis stain-
ing was performed on eWAT and iWAT harvested from 
both chow-fed wild-type and FXR/ mice expressing aP2-
hFXR and compared with the respective controls. Disorga-
nized ECM was apparent in iWAT from the transgenic 
mice with loss of the characteristic septa that subdivide the 
tissue into subsections (Fig. 4A, supplemental Fig. S3) (45). 
In eWAT, accumulation of collagen was observed that pre-
dominantly surrounded individual adipocytes (i.e., pericel-
lular fibrosis, Fig. 4B, supplemental Fig. S3). The COL1A1 
protein level was also elevated in the eWAT of FXR/ 
aP2-hFXR mice and, in line with the secretome analysis 
(see Fig. 3), COL1A2 was not (Fig. 4C, D). Lamin-A, a 
protein that scales with tissue stiffness (46), was increased 
as well (Fig. 4C, D).
FXR expression in adipose tissue leads to redistribution 
of body fat during HFD feeding
Next, we examined the effects of hFXR overexpression 
on WAT functioning in mice with a positive energy balance 
Fig. 2. Adipose hFXR increases adipocyte size with-
out affecting adipose depot size. A: Distribution of adi-
pocyte size (in percentage) in eWAT and average 
adipocyte size in wild-type (wt) and aP2-hFXR mice. 
Body and WAT weight (B), eWAT morphology (C), 
and distribution and average adipocyte size (D) of 
FXR/ and FXR/ aP2-hFXR mice. All panels: n = 
6–8 per group; data are represented as mean ± SEM; 
*P < 0.05. Scale bar represents 100 m.
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induced by feeding a HFD for 6 weeks (60% of calories 
from fat). Whereas WAT depots of control mice expanded 
(2.5-fold, Fig. 5A), those of aP2-hFXR mice remained 
similar in size to chow-fed conditions (only 1.1- to 1.4-fold 
expansion, compare dotted line to bar). Adipocytes from 
HFD-fed wild-type mice were markedly larger than those 
from mice fed on chow, while adipocytes from aP2-hFXR 
mice remained as hypertrophic as observed during chow-
fed conditions (Fig. 5B, C; supplemental Fig. S4A). Both 
absorption of dietary fat and locomotor activity were unaf-
fected and, in contrast to chow-fed conditions, cumulative 
food intake was similar in both groups (supplemental Fig. 
S4B–D). No differences in energy expenditure were ob-
served between the groups either (supplemental Fig. S4E). 
This unexpected inability for WAT to expand was subse-
quently also observed in an ageing experiment. The mass 
of WAT compartments was significantly increased by 2.5-
fold in aged (1 year old) chow-fed wild-type mice when 
compared with 14-week-old mice. In contrast, ageing of 
aP2-hFXR mice hardly induced any expansion of WAT de-
pots that, like the aged controls, contained hypertrophic 
adipocytes with even smaller size compared with young 
aP2-hFXR mice (Fig. 5D–F, supplemental Fig. S4F).
FXR/ mice were shown to be resistant to diet-induced 
obesity (27), and FXR/ aP2-hFXR mice were therefore 
also fed the HFD. This resulted in similar weight gains (5.0 g 
or 19% vs. 5.3 g or 23% for FXR/ and FXR/ aP2-hFXR 
mice, respectively; Fig. 5G), indicating that adipocytic Fxr 
is not responsible for the suppressive effect of Fxr ablation 
on development of diet-induced obesity. aP2-driven FXR 
overexpression in the FXR/ background did result in a 
small but significant increase in adipocyte size in eWAT 
Fig. 3. Adipose hFXR affects transcriptional and 
translational processes associated with the ECM forma-
tion. A: Functional annotation categorization of aP2-
hFXR versus wild-type eWAT transcriptomics, showing 
David top 10 of enriched cellular components and 
GSEA. B: Secretome analysis of eWAT ex vivo showing 
statistically significant decreased/increased protein 
levels as well as aP2-hFXR-specific proteins identified 
according to cellular localization.
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and iWAT but not in rWAT after 6 weeks of HFD (Fig. 5H, I; 
supplemental Fig. S4G). Adipose depot size, however, 
remained similar to chow-fed conditions and lacked the 
expansion observed in FXR/ controls (Fig. 5G). Fibrosis 
staining again showed a disorganized ECM in iWAT of 
FXR/ aP2-hFXR mice; however, as expected, septa were 
also not readily observed in FXR/ controls after HFD 
(Fig. 5J). Similar to chow-fed mice, fibrosis staining was 
more pronounced in eWAT of FXR/ aP2-hFXR mice, 
however, in FXR/ control animals also, fibrotic patches 
became apparent after HFD feeding, as occurs in wild-
type animals as well (Fig. 5K) (45). In line with the above, 
the increased expression of ECM-encoding genes observed 
in eWAT of chow-fed aP2-hFXR mice was not apparent any-
more after HFD in eWAT of FXR/ aP2-hFXR compared 
with FXR/ controls with only a trend for increased 
Col1a1. This implies that the development of fibrosis oc-
curred already early during development on standard 
chow conditions and is matched by the control animals 
during a positive energy balance (supplemental Fig. S4H). 
Similar to the unaltered expression of inflammatory 
markers in eWAT and macrophages on the wild-type 
background, expression of Cd68, Tnf, Mcp1, and Il10 in 
eWAT and liver of chow- or HFD-fed FXR/ aP2-hFXR 
mice was not altered compared with controls. Crown-
like structure abundance also remained unaffected 
(supplemental Table S5).
Adipocytic FXR-induced ectopic lipid accumulation 
aggravates insulin resistance
To determine whether the impaired expansion capacity 
of adipose depots in aP2-hFXR mice has adverse metabolic 
consequences, lipid contents in plasma and organs were 
analyzed. Plasma free fatty acids tended to be elevated in 
chow-fed FXR/ aP2-hFXR mice when compared with 
FXR/ controls and were significantly elevated after HFD 
(Fig. 6A). Free fatty acids were also elevated in aP2-hFXR 
mice on wild-type background relative to controls both on 
chow and on HFD (supplemental Fig, S5A). After HFD 
feeding for 6 weeks, ectopic lipid accumulation in both 
liver and muscle tended to occur in hFXR-overexpressing 
mice on wild-type background as well, indicating that limi-
tation of adipose depot expansion capacity due to the pres-
ence of adipocytic hFXR leads to ectopic fat accumulation, 
particularly in the liver (supplemental Fig. S5B–D). Of 
note, the livers of chow-fed aP2-hFXR mice appeared to be 
very similar to those of control animals, as confirmed by 
the absence of elevated aminotransferases in plasma and 
histological signs of liver damage. To exclude potential 
contributions of unknown indirect effects on hepatic lipid 
accumulation, e.g., due to dysregulation of hepatic acetyl-
CoA metabolism leading to excess hepatic lipogenesis 
(47), the origin of hepatic fatty acids was determined. 
Quantification of de novo lipogenesis in vivo by a mass iso-
topomer distribution analysis approach (48) revealed the 
Fig. 4. Adipose hFXR causes collagen deposition 
and alters adipose architecture. Collagen characteriza-
tion in iWAT (A) and eWAT (B) of chow-fed FXR/ 
and FXR/ aP2-hFXR mice by picrosirius red stain-
ing. Collagen I and lamin-A/C protein levels (C) and 
quantification in eWAT of chow-fed FXR/ and 
FXR/ aP2-hFXR mice (D) (n = 6; data are repre-
sented as mean ± SEM; *P < 0.05, **P < 0.01). Scale bar 
represents 200 m.
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presence of virtually identical amounts of fatty acids de-
rived from de novo lipogenesis and from chain elongation, 
indicating that stimulation of these pathways does not drive 
the accumulation of hepatic triglycerides in aP2-hFXR 
mice on HFD (supplemental Fig. S5E). This observation, 
combined with elevated free fatty acid levels in plasma, 
strongly suggests that hepatic fat accumulation is due to an 
overflow from adipocytic fat stores.
A similar trend in hepatic triglyceride accumulation after 
6 weeks on HFD was observed in FXR/ aP2-hFXR mice 
compared with FXR/ controls (supplemental Fig. S5F, G). 
To elaborate on these metabolic consequences, we next 
Fig. 5.  HFD prevents further growth of hypertrophic adipocytes in aP2-hFXR mice and fat depot expansion is limited. A: Body and WAT 
weight of wild-type (wt) and aP2-hFXR mice after 6 weeks of HFD. The dotted lines indicate WAT weights of chow-fed mice (presented in 
Fig. 1). eWAT morphology (B) and distribution and average of adipocyte size (C) after 6 weeks of HFD. D: Body and WAT weight of 1-year-old 
chow-fed wild-type and aP2-hFXR mice. eWAT morphology (E) and distribution and average adipocyte size (F) of 1-year-old wild-type and 
aP2-hFXR mice. G: Body and WAT weight of FXR/ aP2-hFXR mice after 6 weeks of HFD. Dotted lines indicate weights of chow-fed control 
animals (depicted in Fig. 2). eWAT morphology (H) and distribution of adipocyte size and average adipocyte size (I) of FXR/ aP2-hFXR 
mice after 6 weeks of HFD. Sirius red fibrosis staining of iWAT (J) and eWAT (K) after 13 weeks of HFD (n = 6–9 per group; data are repre-
sented as mean ± SEM; *P < 0.05). Scale bar represents 100 m.
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Fig. 6. Obesogenic conditions induce ectopic lipid accumulation and insulin resistance in aP2-hFXR mice. A: Plasma free fatty acid levels 
of chow- and HFD-fed FXR/ and FXR/ aP2-hFXR mice. B: Fat mass of FXR/ and FXR/ aP2-hFXR mice after 3 months of HFD. C: 
Liver H&E staining showing lipid accumulation that is most apparent in the pericentral zone. Top scale bars in panel C depict 500 m, 
bottom scale bars in enlargements depict 200 m. Hepatic triglycerides (D) and hepatic total cholesterol (E) of FXR/ and FXR/ aP2-
hFXR mice after prolonged HFD. Plasma total cholesterol (F) and triglycerides (G) of FXR/ and FXR/ aP2-hFXR mice after 3 months 
of HFD. Gastrocnemius triglycerides of FXR/ and FXR/ aP2-hFXR mice after 3 months of HFD (H) and plasma bile acid composition (I). 
(J) Four hour-fasted plasma insulin (J) and blood glucose (K) of chow- and HFD-fed FXR/ and FXR/ aP2-hFXR mice. Metabolic clear-
ance rate (L), turnover rate (that under these conditions equals glucose production) (M), and peripheral and hepatic insulin sensitivity (N) 
during a whole-body glucose test of FXR/ and FXR/ aP2-hFXR mice after 3 months of HFD (n = 6–8 per group; data are represented as 
mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
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extended the duration of a positive energy balance to 
3 months in FXR/ and FXR/ aP2-hFXR mice, because 
FXR/ mice have been reported to be resistant to diet- 
induced obesity (27). To test whether these mice simply store 
less fat, total fat mass was determined by MRI, which showed 
that more fat actually accumulated in FXR/ aP2-hFXR 
mice than in FXR/ controls after this prolonged period 
of HFD feeding (Fig. 6B). Within this period, significantly 
more triglycerides and cholesterol accumulated in the 
livers of FXR/ aP2-hFXR mice than in those of FXR/ 
mice (Fig. 6C–E).
Plasma cholesterol levels were slightly elevated in FXR/ 
aP2-hFXR mice, whereas plasma triglycerides remained 
similar to those in FXR/ controls (Fig. 6F, G). Muscle tri-
glyceride content was significantly elevated in FXR/ aP2-
hFXR mice after 3 months on HFD (Fig. 6H). The FXR/ 
aP2-hFXR mice tended toward elevated plasma bile acids 
after 3 months on HFD, but were not altered, most probably 
due to the known dominant effect of whole-body FXR 
ablation that shifts the bile acid composition toward pre-
dominantly taurocholate in both groups (Fig. 6I, supple-
mental Fig. S5I) (49, 50). The differences in adipose depot 
size between both groups remained similar to the differ-
ences observed after 6 weeks of HFD feeding, indicating 
that the storage capacity of WAT depots rapidly became lim-
iting in the FXR/ aP2-hFXR mice; whereas in the FXR/ 
control animals, the positive energy balance could largely 
be matched by adipose storage capacity during the experi-
ment (supplemental Fig. S5J).
Ectopic lipid accumulation, accompanied by increased 
concentrations of intermediates of lipid metabolism, such 
as diacylglycerols and ceramides, is one of the drivers of in-
sulin resistance (51). Therefore, we analyzed glucose kinet-
ics by a dynamic stable isotope test. Compared with FXR/ 
controls, HFD-fed FXR/ aP2-hFXR mice showed similar 
blood glucose levels; yet, insulin levels were 3-fold higher 
(Fig. 6J, K). Of note, after 6 weeks of HFD, insulin levels 
were unaltered in FXR/ aP2-hFXR mice compared with 
controls (also on the wild-type background, supplemental 
Fig. S5K, L) indicating that the lack of adipose expansion 
capacity precedes elevated insulin levels after prolonged 
obesogenic conditions. Determination of glucose kinetics 
under normoglycemic conditions, using a stable isotopi-
cally labeled glucose tracer (34), showed that metabolic 
clearance rates and glucose production rates were similar 
in FXR/ aP2-hFXR and FXR/ control mice, yet, at the 
expense of 3-fold increased insulin levels due to a marked 
hepatic and peripheral insulin resistance (Fig. 6L–N). 
Overall, these data indicate that moderate aP2-controlled 
overexpression of human FXR in fat tissues results in adi-
pocyte hypertrophy and limited WAT expansion capacity 
when challenged with HFD, leading to ectopic lipid accu-
mulation and insulin resistance.
DISCUSSION
The studies presented here establish that the bile acid-
activated nuclear receptor, FXR, may contribute to the 
regulation of fat tissue function and architecture. We show 
that transgenic mice that moderately overexpress hFXR 
(3- to 5-fold compared with endogenous Fxr) under the 
control of the aP2 (Fabp4) promoter have WAT with en-
larged adipocytes under standard chow-fed conditions. 
On a HFD as well as at a moderately old age, these mice 
show very limited expansion of WAT depots and an inabil-
ity to further increase adipocyte size. In accordance with a 
limited storage capacity of WAT due to this localized FXR 
overexpression, ectopic lipid deposition occurred during 
conditions of a positive energy balance on both wild-type 
and whole-body FXR/ backgrounds. Extensive ECM 
remodeling was observed and may be involved in this 
unexpected action of FXR in regulating adipose tissue 
architecture. It is of importance to note that the expression 
levels of hFXR in adipose tissues reached in our models 
were still low compared with the expression of endogenous 
Fxr in liver and intestine, at least at the RNA level. This may 
reflect a low expression per adipocyte or, alternatively, ex-
pression in a subset of cells. It is evident that additional 
studies, e.g., by employing adipose-specific FXR-deficient 
mouse models, are warranted to unequivocally establish 
the (patho)physiological role of FXR in adipose biology.
Although the temporal dynamics of expansion differ for 
specific WAT depots and different developmental stages 
have distinct molecular underpinnings of adipogenesis 
(43, 52, 53), hFXR-associated hypertrophy and limited 
expansion capacity were observed in all depots analyzed 
and at different ages of the mice, suggesting a fundamental 
role for this nuclear receptor in adipose biology. In line 
with the “critical fat cell size” hypothesis (54), the hypertro-
phic adipocytes in aP2-hFXR mice did not increase further 
in size during a positive energy balance, and depot size 
also did not increase; therefore, hyperplasia must be sup-
pressed under these conditions. This was confirmed by the 
reduced depot size of FXR-overexpressing mice shortly 
after birth; although FXR has been proposed to be a posi-
tive regulator of adipogenesis in vitro (25, 26). The adi-
pose micro-environment in the in vivo situation therefore 
seems to predominate over potential positive effects of FXR 
activity on adipogenesis; however, to confirm that FXR 
does not affect Wnt signaling in vivo requires a more thor-
ough investigation of pre-adipocytes in WAT.
Interestingly, prolonged treatment with an FXR agonist 
during obesogenic conditions also seems to result in adipo-
cyte hypertrophy (55). The observation that, in aged mice 
overexpressing hFXR, expansion of adipose depots was also 
limited and that adipocyte size in eWAT was even decreased 
compared with young mice (compare Fig. 2A to Fig. 5F) is 
in line with inhibition of adipose plasticity upon FXR over-
expression. The eWAT depot is known to have a high depen-
dency on newly formed cells, a process that declines with 
age (56, 57). Fxr expression was reported to decrease in 
WAT during genetic and diet-induced obesity in mice (24). 
We now provide suggestive evidence that this effect may in 
fact liberate WAT plasticity, providing increased storage 
capacity upon excessive energy intake.
The wild-type and FXR/ backgrounds did result in sub-
tle differences concerning the effects on WAT expansion 
and adipocyte size by FXR overexpression (i.e., compare 
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Fig. 5C to Fig. 5I), suggesting that external FXR-mediated 
cues on adipose FXR function do exist. Of note, although 
the reported reduced adipocyte size in FXR/ mice was one 
of the major reasons for us to focus on adipocytic FXR (24), 
the complete FXR knockout model used in this study dis-
played similar adipocyte size as wild-type mice did (com-
pare Fig. 2A to Fig. 2D) (50), and thus lacked the smaller 
adipocytes observed earlier in FXR/ mice generated by 
Cre-mediated deletion of the last exon (24). Possibly, the 
latter model might still produce a truncated form of FXR 
that contains the DNA-binding domain (50). When com-
paring the wild-type and FXR-deficient backgrounds, how-
ever, the large shift in bile acid pool size and composition 
due to lack of hepatic and intestinal FXR could affect the 
function of adipose FXR, as ligand availability in plasma is 
dramatically altered (58). As observed previously (59), we 
also identified expression of organic anion transporting 
polypeptide 2B1 (Oatp2b1; Slc2b1), a transporter with ubiq-
uitous expression that may facilitate adipocytic bile acid 
uptake. Unexpectedly, adipose FXR overexpression re-
sulted in elevated plasma bile acids with a more hydropho-
bic composition, which may generate a feedforward loop 
toward adipose FXR activation. Analysis of expression of 
hepatic bile acid synthesis genes on which both intestinal 
and hepatic FXR activity converges, revealed only a minor 
reduction in Cyp7b1, Cyp27a1, and Cyp2c70 and no effect 
on Shp expression or the major bile acid synthesis genes, 
Cyp7a1 and Cyp8b1, that are regulated by SHP downstream 
of hepatic FXR.
Yet, Ntcp and Oatp1a1 were over 2-fold downregulated, 
suggesting that impaired hepatic uptake of bile acids is 
responsible for the observed accumulation of bile acids in 
plasma. The underlying mechanism hereof, suggesting ad-
ipose-liver cross-talk, remains elusive. Adipose tissue forma-
tion during late fetal and early postnatal life in humans is 
highly sensitive to the nutritional environment and coincides 
with the period of so-called “physiological cholestasis” in 
newborns (elevated plasma concentrations of primary bile 
acids) (60). Bile acids acting as an endogenous ligand for 
FXR in adipose tissue that contribute to regulation of adi-
pogenesis are therefore of potential importance during 
this stage of development.
Adipose transcriptomics and ex vivo secretome analysis 
revealed broad changes in the adipose ECM upon FXR 
overexpression. Recent interest in the cues that determine 
the fate of stem cells toward a specific lineage have under-
lined the importance of the microenvironment in which 
these cells reside and, in particular, the properties of the 
ECM (61). The stiffness of the matrix defines the plasticity 
of the stem cell/pre-adipocyte population: nuclear lamin 
A, a component of one of the mechano-sensing mecha-
nisms, strongly scales with tissue stiffness (46). Mastering 
these parameters of the microenvironment in which stem 
cells are directed toward a desired fate has been instrumen-
tal in enabling stem cell research, tissue regeneration, and 
the production of organoids (62). Also in adipose tissue, 
ECM homeostasis and remodeling according to prevailing 
tissue needs is an important high-maintenance process, 
which is particularly evident in mature adipocytes (63). 
Based on our results, we propose that FXR-induced altera-
tions in ECM homeostasis (co-)dictate adipocyte hyperplasia 
and fat depot expansion. Control of the adipocyte micro-
environment has recently also been shown to be regulated 
by a specific subset of adipocyte progenitors (64). These 
cells, which are positive for platelet-derived growth factor 
receptor  or , seem to derive from a common progenitor 
as pre-adipocytes destined to mature into adipocytes. These 
cells therefore seem to be at the crossroad between healthy 
and unhealthy adipose tissue development (65, 66). Despite 
the fact that the adiponectin promotor has become the 
preferred tool for generating adipocyte-specific knockout 
mice, the aP2-driven model applied in this study has the 
advantage that it also targets the adipocyte precursors. 
Whether FXR already alters the developmental trajectory 
of these progenitors with increased tissue stiffness as a 
consequence or acts further down the line, for instance 
by altering this lamin A-based sensing mechanism (67), 
remains to be established.
Paradoxically, the Scherer laboratory revealed that, next 
to its infamous role in metabolic disease, inflammation of 
adipose tissue is actually required for healthy expansion as 
well (68). Although the level of expression in adipose tis-
sue is more than 1,000-fold higher than in adipose-resident 
macrophages (69), we were able to detect hFXR mRNA in 
isolated macrophages in our model. However, no effect 
was observed on inflammatory markers or the abundance 
of crown-like structures, or even on the expression of FXR 
target genes in macrophages, strongly suggesting that the 
off-target expression is very limited; although we cannot 
definitely rule out a role for macrophage FXR. One phe-
nomenon in our model that could possibly be explained by 
non-adipocyte expression is the highly intriguing reduc-
tion in lean body mass. Although we think that it is tempt-
ing to speculate that an adipocyte-derived factor is causal to 
this phenotype, we were unable to identify major changes 
in known adipokines that regulate lean mass development. 
Further studies are therefore required to determine the 
cause of this highly interesting phenotype.
The increased plasma free fatty acid levels that were 
observed already under chow-fed conditions suggests that 
WAT storage capacity is limited but can systemically still be 
compensated for. Yet, exposure to a positive energy balance 
provokes ectopic lipid accumulation in liver and muscle. As 
adipose-derived fatty acid flux contributes 60–80% of the 
hepatic lipid influx in both mice and men, subtle changes 
in adipose output may lead to severe hepatic consequences 
over time (70, 71). Recently, for instance, adipose tissue 
lipolysis rates were found to drive hepatic glucose produc-
tion (47). The observed elevated plasma levels of free fatty 
acids in our model, indicative of an increased rate of lipoly-
sis, did not lead to increased glucose production. Yet, ectopic 
lipid accumulation was associated with evident insulin resis-
tance, which delineates a pathophysiological relevance for 
adipocytic FXR in whole-body energy metabolism.
In conclusion, our studies establish that the nuclear 
receptor, FXR, is a determinant of fat tissue function and 
architecture, among others, by control of ECM remodel-
ing, which adds to the extended list of FXR functionalities 
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(2, 5). Our work thus provides new insights into the contri-
bution of FXR in the maintenance of whole-body energy 
balance, in addition to its better understood functions in 
liver and intestine. In view of the current development of 
FXR agonists for treatment of human metabolic diseases, 
potential fat-specific actions of these compounds must be 
considered.
Mouse aP2 promoter and human FXR2-expressing plasmids 
were kindly provided by Dr. R. E. Hammer (Department of 
Biochemistry and the Howard Hughes Medical Institute, 
University of Texas Southwestern Medical Center, Dallas, 
TX) and Dr. R. Mukherjee (Bristol-Myers Squibb Company, 
Experimental Station, Wilmington, DE).
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